Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2020

View Archived Issues

Transplanted iPSCs are best of both ApoE models

Keros completes dosing of planned cohorts in phase I study of KER-047

Oral RECCE-435 shows efficacy in animal model of H. pylori infection

Huya Bioscience obtains worldwide rights to SHP-2 inhibitor

IBC-Ab002 shows promising safety and efficacy in models of AD

p53 plays role of Dr. Jekyll or Mr. Hyde in gastric cancer

Betta Pharmaceuticals divulges EGFR mutant inhibitors

Merck & Co. discloses new compounds for tuberculosis

Chinese researchers present new mu-opioid receptor agonists

New HER2 inhibitors presented by Taiho Pharmaceutical

Voronoi patent details RIP-1 inhibitors

IMV receives funding for phase I study of DPX-COVID-19 vaccine

MODAG completes first phase I study of Anle-138b

Revive finalizing details for phase III study of bucillamine in COVID-19

HTA presents new prostate cancer diagnosis probe [68Ga]DOTA-ANCP-PSMA

Positive preliminary data presented from diverticulosis pilot trial of PGLG

Personalized TLPLDC vaccine demonstrates long-term survival benefit in high-risk melanoma

Phase III study of CS-1001 as first-line treatment of NSCLC meets primary endpoint

Genetic variant in IFITM3 gene tied to disease severity in COVID-19 disease

FDA approves Blenrep for relapsed or refractory multiple myeloma

Lundbeck discontinues phase II study of Lu-AF-11167

Phase II study of BioAegis' gelsolin for COVID-19 begins in Spain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.